SOLICITATION NOTICE
Q -- Analysis of Slides for the Tamoxiden and Mammographic Density Study
- Notice Date
- 6/28/2012
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-120094-EB
- Archive Date
- 7/28/2012
- Point of Contact
- Erin M. Breedlove, Phone: 3014968607, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
breeerin@mail.nih.gov, cr214i@nih.gov
(breeerin@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6068, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI) plans to procure on a sole source basis with Kaiser Foundation Health Plan, Inc, 3900 N. Interstate, Portland, OR 97227 for analysis of slides for the Tamoxifen and Mammographic Density Study. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The North American Industry Classification System code is 541380 and the business size standard is $12M. Period of performance is for twelve months from time of award. It has been determined that there is no opportunity to acquire green products or services under this contract. Numerous studies have demonstrated that tamoxifen treatment reduces the risk of ER-positive breast cancer recurrence and death when compared to placebo. Data also show that tamoxifen reduces breast density and in the chemopreventive setting a decline in mammographic density following tamoxifen treatment is linked to risk reduction. NCI shall evaluate whether changes in mammographic density are related to breast cancer recurrence and/or death among KPNW breast cancer patients with ER-positive disease in the setting of adjuvant tamoxifen treatment. The contractor shall provide existing hematoxylin and eosin-stained pathology slides for approximately 500 primary breast cancer patients for pathological review by NCI personnel at Kaiser Permanent Northwest, and to retrieve, pack, and ship NCI selected slides and matched formalin-fixed paraffin-embedded tissue blocks for these cases. This tissue will be analyzed as part of a nested case-control study conducted by NCI. Data will be used to assess the effect of breast tissue characteristics on the relationship between changes in breast density and breast cancer recurrence and/or death among ER-positive breast cancer patients treated with adjuvant tamoxifen at Kaiser Permanent Northwest. This is an ongoing project for the NCI Kaiser Tamoxifen and Mammographic Density Study. The requested scope of this work can only be completed at Kaiser Permanent Northwest. This procurement relates to an ongoing project, the NCI/DCEG/HREB Kaiser Tamoxifen and Mammographic Density Study. To conduct the proposed analyses of the effect of tissue characteristics on the relationship between change in mammographic density and breast cancer recurrence and/or death requires the retrieval of archival tissue specimens from the patients in NCI/DCEG/HREB Kaiser Tamoxifen and Mammographic Density Study. All patients were treated at KPNW and their archival tissue specimens are stored and maintained by KPNW. Therefore, KPNW is the only source for pathology materials related to this project. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on July 13, 2012. No electronic capability statements will be accepted (i.e. email or fax), an original and one copy must be sent to the NCI Office of Acquisitions at the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Erin Breedlove, Contract Specialist at breeerin@nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-120094-EB on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-120094-EB/listing.html)
- Record
- SN02789030-W 20120630/120628235245-fc77ae14b556b8edd39463d00a523521 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |